Fujisawa Protopic Dermatitis Second-Line Therapy Use Suggested By Cmte.

Fujisawa's Protopic (tacrolimus) atopic dermatitis treatment should be reserved for use as a second-line alternative following inadequate response to conventional drugs, FDA's Dermatologic & Ophthalmic Drugs Advisory Committee recommended Nov. 16.